OSCAR HEALTH INC

Company Overview

Oscar Health is a technology-driven health insurer focused on the ACA individual market and a growing B2B licensing arm (+Oscar) that provides engagement tools to other payors and providers. It sells predominantly EPOs (and select HMOs) across 18 states, derives nearly all revenue from premiums (heavily dependent on CMS-administered APTCs), and reported rapid membership growth (≈1.68M effectuated members at 12/31/24 and ≈2.03M by Q2 2025). The business model emphasizes a proprietary cloud-native technology stack, virtual care and member Care Teams, and uses reinsurance and risk-transfer mechanisms to manage primary claims exposure. Key operational and market risks include heavy federal/state regulation, variability in risk adjustment and reserves, seasonal enrollment dynamics, and vendor/cloud dependencies.

Executive Compensation Practices

At Oscar, compensation is likely calibrated to both growth and underwriting performance: membership and premium growth, adjusted EBITDA/net income, retention/engagement metrics (e.g., NPS), and medical loss ratio/risk-adjustment outcomes will be primary short- and long-term incentive drivers. Given the company’s “tech + insurance” profile and recent rapid scale-up, pay packages are typically equity-heavy (RSUs/options and performance-based equity) to align executives with long‑term membership expansion, platform licensing (+Oscar) adoption, and stock‑price appreciation. Variable cash incentives may be tied to regulatory and capital metrics (statutory capital, RBC, and successful reinsurance renewals) because state insurance rules and subsidiary capitalization materially constrain cash distributions and parent liquidity. Compensation programs should also include clawbacks or adjustments tied to reserve and risk‑adjustment estimate reversals, since benefit payable and RA judgments can materially swing results.

Insider Trading Considerations

Material, non‑public information for Oscar is frequently event‑driven: enrollment and SEP updates, quarterly premium and MLR trends, large risk‑adjustment or reinsurance payments, morbidity data revisions, regulatory rulings (e.g., APTC changes, CMS program integrity), and M&A or convertible‑note conversion events. Insiders are therefore likely to observe stricter blackout windows around open enrollment/SEP periods and financial releases, and many will use Rule 10b5‑1 plans to manage planned trades; Section 16 short‑swing rules and state insurance holding‑company oversight can further constrain timing and disclosures. Watch Form 4 activity around membership inflection points, reinsurance or RADV announcements, and the 2031 convertible‑note conversion window (Q3 2025), since buys can signal conviction on near‑term membership/capital prospects while sales may reflect tax, diversification or holding‑company liquidity needs.